Zymeworks Inc. to Post Q1 2025 Earnings of ($0.47) Per Share, HC Wainwright Forecasts (NYSE:ZYME)

Zymeworks Inc. (NYSE:ZYME) – Analysts at HC Wainwright lowered their Q1 2025 earnings estimates for Zymeworks in a research report issued to clients and investors on Wednesday, September 25th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.47) per share for the quarter, down from their previous forecast of ($0.45). HC Wainwright has a “Neutral” rating and a $12.00 price objective on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($0.85) per share. HC Wainwright also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.55) EPS and FY2025 earnings at ($2.05) EPS.

Separately, Stifel Nicolaus upped their price target on shares of Zymeworks from $20.00 to $21.00 and gave the company a “buy” rating in a report on Friday, August 2nd.

Zymeworks Trading Down 0.4 %

Shares of Zymeworks stock opened at $12.42 on Friday. Zymeworks has a 1-year low of $6.01 and a 1-year high of $13.27. The firm has a fifty day simple moving average of $11.28 and a 200-day simple moving average of $9.94. The stock has a market capitalization of $878.16 million, a price-to-earnings ratio of -6.94 and a beta of 1.19.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. Zymeworks had a negative return on equity of 21.97% and a negative net margin of 179.42%. The business had revenue of $19.24 million for the quarter, compared to the consensus estimate of $23.16 million. During the same period last year, the business earned ($0.76) EPS.

Institutional Investors Weigh In On Zymeworks

A number of institutional investors have recently bought and sold shares of the business. AlphaMark Advisors LLC acquired a new position in shares of Zymeworks in the 1st quarter worth approximately $32,000. Quest Partners LLC lifted its holdings in shares of Zymeworks by 8,049.6% during the second quarter. Quest Partners LLC now owns 9,209 shares of the company’s stock valued at $78,000 after acquiring an additional 9,096 shares during the period. MQS Management LLC bought a new position in shares of Zymeworks during the second quarter valued at $92,000. Tocqueville Asset Management L.P. acquired a new stake in shares of Zymeworks in the 1st quarter valued at $117,000. Finally, Arizona State Retirement System grew its holdings in shares of Zymeworks by 11.1% in the 2nd quarter. Arizona State Retirement System now owns 12,841 shares of the company’s stock worth $109,000 after purchasing an additional 1,285 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.